Boehringer Ingelheim Pharmaceuticals, Inc.
NEWS
Therapeutics to halt the progression of chronic kidney disease are in Phase III trials, and others will enter that stage soon. NDAs could follow as early as 2024 with regulatory determinations in 2025.
Surrozen announced it paused its Phase I study in Crohn’s disease and ulcerative colitis as several healthy participants showed increased levels of liver enzymes.
Surrozen announced Thursday it has partnered with Boehringer Ingelheim to research and develop a therapeutic for the treatment of retinal diseases.
Boehringer announced that the FDA approved Spevigo for generalized pustular psoriasis flares in adults, the first drug approved for this indication.
Recent advances in precision medicine and genomics have launched an explosion in immunotherapies that are resulting in real cures and earlier diagnoses - and more healthy years for individuals.
Boehringer, Evotec and bioMérieux found Aurobac to combat antimicrobial resistance, Turnstone and Moffitt Expand TIL Collab, Skyhawk to gain potential $2B from Sanofi RNA splicing deal.
Many healthcare, pharmaceutical and biotech companies continue to place their bets on China, bringing fresh rounds of investments to and forging new partnerships with local firms.
Illumina and Deerfield Management have entered into a five-year partnership to apply a genetic-led approach to the discovery and development of novel therapies.
Amphista Therapeutics forged two significant protein degradation partnerships with big pharma. Wednesday, the U.K.-based company announced partnerships with both Bristol Myers Squibb and Merck KGaA that have a combined value of more than $2 billion.
JOBS
IN THE PRESS